View in EDS

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.

Saved in:
Bibliographic Details
Title: In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
Authors: Vafai SB; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Täubel J; Richmond Pharmacology, London.; St. George's University of London, London., Ashdown T; Richmond Pharmacology, London., Patel RS; Institute of Cardiovascular Science, University College London, London.; Barts Health NHS Trust, London., Diamondali S; Barts Health NHS Trust, London., Cegla J; Imperial College London, London., Soran H; National Institute for Health and Care Research-Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Bashir B; National Institute for Health and Care Research-Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Abitbol A; LMC Diabetes and Endocrinology, Toronto.; Centricity Research, Toronto., Gaudet D; Department of Medicine, Université de Montréal, Montreal.; ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada., Lauzière A; Department of Medicine, Université de Montréal, Montreal.; ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada., Brunham LR; Department of Medicine, University of British Columbia, Vancouver, Canada.; Healthy Heart Program Prevention Clinic, St. Paul's Hospital, Vancouver, BC, Canada., Newby DE; British Heart Foundation Centre for Research Excellence, University of Edinburgh, Edinburgh., Nicholls SJ; Victorian Heart Institute, Monash University, Melbourne, VIC, Australia., Scott RS; New Zealand Clinical Research, Christchurch, New Zealand., Kerr J; New Zealand Clinical Research, Christchurch, New Zealand., Tardif JC; Montreal Heart Institute, Université de Montréal, Montreal., Lunken C; University College London Hospitals NHS Foundation Trust, London., Humphries SE; Institute of Cardiovascular Science, University College London, London., Karsten V; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Tyler PD; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Zhang X; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Huniti N; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Flight PA; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Jensen CL; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Falzone R; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Biedenkapp JC; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Lister T; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Stolz LE; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Khera AV; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston., Kathiresan S; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.
Source: The New England journal of medicine [N Engl J Med] 2026 May 25. Date of Electronic Publication: 2026 May 25.
Publication Type: Journal Article
Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42187087
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Vafai+SB%22">Vafai SB</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Täubel+J%22">Täubel J</searchLink>; Richmond Pharmacology, London.; St. George's University of London, London.<br /><searchLink fieldCode="AU" term="%22Ashdown+T%22">Ashdown T</searchLink>; Richmond Pharmacology, London.<br /><searchLink fieldCode="AU" term="%22Patel+RS%22">Patel RS</searchLink>; Institute of Cardiovascular Science, University College London, London.; Barts Health NHS Trust, London.<br /><searchLink fieldCode="AU" term="%22Diamondali+S%22">Diamondali S</searchLink>; Barts Health NHS Trust, London.<br /><searchLink fieldCode="AU" term="%22Cegla+J%22">Cegla J</searchLink>; Imperial College London, London.<br /><searchLink fieldCode="AU" term="%22Soran+H%22">Soran H</searchLink>; National Institute for Health and Care Research-Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Bashir+B%22">Bashir B</searchLink>; National Institute for Health and Care Research-Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Abitbol+A%22">Abitbol A</searchLink>; LMC Diabetes and Endocrinology, Toronto.; Centricity Research, Toronto.<br /><searchLink fieldCode="AU" term="%22Gaudet+D%22">Gaudet D</searchLink>; Department of Medicine, Université de Montréal, Montreal.; ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Lauzière+A%22">Lauzière A</searchLink>; Department of Medicine, Université de Montréal, Montreal.; ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Brunham+LR%22">Brunham LR</searchLink>; Department of Medicine, University of British Columbia, Vancouver, Canada.; Healthy Heart Program Prevention Clinic, St. Paul's Hospital, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Newby+DE%22">Newby DE</searchLink>; British Heart Foundation Centre for Research Excellence, University of Edinburgh, Edinburgh.<br /><searchLink fieldCode="AU" term="%22Nicholls+SJ%22">Nicholls SJ</searchLink>; Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Scott+RS%22">Scott RS</searchLink>; New Zealand Clinical Research, Christchurch, New Zealand.<br /><searchLink fieldCode="AU" term="%22Kerr+J%22">Kerr J</searchLink>; New Zealand Clinical Research, Christchurch, New Zealand.<br /><searchLink fieldCode="AU" term="%22Tardif+JC%22">Tardif JC</searchLink>; Montreal Heart Institute, Université de Montréal, Montreal.<br /><searchLink fieldCode="AU" term="%22Lunken+C%22">Lunken C</searchLink>; University College London Hospitals NHS Foundation Trust, London.<br /><searchLink fieldCode="AU" term="%22Humphries+SE%22">Humphries SE</searchLink>; Institute of Cardiovascular Science, University College London, London.<br /><searchLink fieldCode="AU" term="%22Karsten+V%22">Karsten V</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Tyler+PD%22">Tyler PD</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Huniti+N%22">Huniti N</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Flight+PA%22">Flight PA</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Jensen+CL%22">Jensen CL</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Falzone+R%22">Falzone R</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Biedenkapp+JC%22">Biedenkapp JC</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Lister+T%22">Lister T</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Stolz+LE%22">Stolz LE</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Khera+AV%22">Khera AV</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.<br /><searchLink fieldCode="AU" term="%22Kathiresan+S%22">Kathiresan S</searchLink>; Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220255562%22">The New England journal of medicine</searchLink> [N Engl J Med] 2026 May 25. <i>Date of Electronic Publication: </i>2026 May 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Massachusetts+Medical+Society%22">Massachusetts Medical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0255562 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1533-4406 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200284793%22">00284793 </searchLink><i>NLM ISO Abbreviation: </i>N Engl J Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42187087
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1056/NEJMoa2601283
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Vafai SB
      – PersonEntity:
          Name:
            NameFull: Täubel J
      – PersonEntity:
          Name:
            NameFull: Ashdown T
      – PersonEntity:
          Name:
            NameFull: Patel RS
      – PersonEntity:
          Name:
            NameFull: Diamondali S
      – PersonEntity:
          Name:
            NameFull: Cegla J
      – PersonEntity:
          Name:
            NameFull: Soran H
      – PersonEntity:
          Name:
            NameFull: Bashir B
      – PersonEntity:
          Name:
            NameFull: Abitbol A
      – PersonEntity:
          Name:
            NameFull: Gaudet D
      – PersonEntity:
          Name:
            NameFull: Lauzière A
      – PersonEntity:
          Name:
            NameFull: Brunham LR
      – PersonEntity:
          Name:
            NameFull: Newby DE
      – PersonEntity:
          Name:
            NameFull: Nicholls SJ
      – PersonEntity:
          Name:
            NameFull: Scott RS
      – PersonEntity:
          Name:
            NameFull: Kerr J
      – PersonEntity:
          Name:
            NameFull: Tardif JC
      – PersonEntity:
          Name:
            NameFull: Lunken C
      – PersonEntity:
          Name:
            NameFull: Humphries SE
      – PersonEntity:
          Name:
            NameFull: Karsten V
      – PersonEntity:
          Name:
            NameFull: Tyler PD
      – PersonEntity:
          Name:
            NameFull: Zhang X
      – PersonEntity:
          Name:
            NameFull: Huniti N
      – PersonEntity:
          Name:
            NameFull: Flight PA
      – PersonEntity:
          Name:
            NameFull: Jensen CL
      – PersonEntity:
          Name:
            NameFull: Falzone R
      – PersonEntity:
          Name:
            NameFull: Biedenkapp JC
      – PersonEntity:
          Name:
            NameFull: Lister T
      – PersonEntity:
          Name:
            NameFull: Stolz LE
      – PersonEntity:
          Name:
            NameFull: Khera AV
      – PersonEntity:
          Name:
            NameFull: Kathiresan S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 05
              Text: 2026 May 25
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1533-4406
          Titles:
            – TitleFull: The New England journal of medicine
              Type: main
ResultId 1